LOS ANGELES, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (Nasdaq:CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar “HOPE-Duchenne: A Clinical Trial for Individuals with Heart Disease Related to DMD” on Tuesday, November 3, 2015 at 3:00 p.m. ET/noon PT.
Speakers include:
• John Jefferies, MD, Study Principal Investigator, Cincinnati Children’s Hospital Medical Center
• Linda Marbán, PhD, CEO, Capricor, Inc.
• Brian Fedor, Study Manager, Capricor, Inc.
• Debra Miller, Founder and Chief Executive Officer of CureDuchenne
• Dr. Michael Kelly, PhD, Chief Scientific Advisor for CureDuchenne
Capricor is testing an investigational cardiac cell therapy to determine if reducing the amount of scar tissue in the heart can lead to better outcomes in Duchenne muscular dystrophy. The HOPE-Duchenne trial will evaluate if an investigational cardiac cell therapy is safe and potentially effective in treating boys and young men with Duchenne. The HOPE-Duchenne trial will study the amount of scar tissue in the heart muscle before and after treatment with either the investigational cardiac cell therapy or usual care. The webinar will provide an overview of the clinical trial which is being conducted at several sites in the U.S. To find a site, see the list on www.ClinicalTrials.gov (Study Identifier NCT02485938).
The HOPE-Duchenne trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. CureDuchenne Ventures invested in Capricor to support the development of its clinical program for Duchenne. Heart failure is the leading cause of death in patients with Duchenne.
To join the webinar please call (844-337-8088) and enter conference ID number 71482322. Visit here: https://cc.readytalk.com/cc/s/registrations/new?cid=sqpn7mtweznr to register online.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy; and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.
About CureDuchenne Ventures and CureDuchenne
CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 boys worldwide. With support from CureDuchenne, three pharmaceutical treatments could be approved by the FDA within the next year. These treatments may lessen the effects of the disease for those with certain mutations of Duchenne, but there is still much to be done to find a cure. For more information, please visit CureDuchenne.org and follow us on Facebook, Twitter and YouTube.
Help employers find you! Check out all the jobs and post your resume.
Speakers include:
• John Jefferies, MD, Study Principal Investigator, Cincinnati Children’s Hospital Medical Center
• Linda Marbán, PhD, CEO, Capricor, Inc.
• Brian Fedor, Study Manager, Capricor, Inc.
• Debra Miller, Founder and Chief Executive Officer of CureDuchenne
• Dr. Michael Kelly, PhD, Chief Scientific Advisor for CureDuchenne
Capricor is testing an investigational cardiac cell therapy to determine if reducing the amount of scar tissue in the heart can lead to better outcomes in Duchenne muscular dystrophy. The HOPE-Duchenne trial will evaluate if an investigational cardiac cell therapy is safe and potentially effective in treating boys and young men with Duchenne. The HOPE-Duchenne trial will study the amount of scar tissue in the heart muscle before and after treatment with either the investigational cardiac cell therapy or usual care. The webinar will provide an overview of the clinical trial which is being conducted at several sites in the U.S. To find a site, see the list on www.ClinicalTrials.gov (Study Identifier NCT02485938).
The HOPE-Duchenne trial will evaluate CAP-1002 for the first time in patients with Duchenne with significant cardiac dysfunction. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. CureDuchenne Ventures invested in Capricor to support the development of its clinical program for Duchenne. Heart failure is the leading cause of death in patients with Duchenne.
To join the webinar please call (844-337-8088) and enter conference ID number 71482322. Visit here: https://cc.readytalk.com/cc/s/registrations/new?cid=sqpn7mtweznr to register online.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy; and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.
About CureDuchenne Ventures and CureDuchenne
CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures LLC was formed by CureDuchenne, a national nonprofit that has a successful track record of supporting research and raising awareness of the disease.
CureDuchenne was founded in 2003 with a focus on saving the lives of those with Duchenne muscular dystrophy, a disease that affects more than 300,000 boys worldwide. With support from CureDuchenne, three pharmaceutical treatments could be approved by the FDA within the next year. These treatments may lessen the effects of the disease for those with certain mutations of Duchenne, but there is still much to be done to find a cure. For more information, please visit CureDuchenne.org and follow us on Facebook, Twitter and YouTube.
Help employers find you! Check out all the jobs and post your resume.
